# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 pric...
Open-label Phase 2 trial in breast cancer to begin this quarterInitial data expected mid-2025HANOVER, Md., July 30, 2024 (GLOBE...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 pric...